Adrianus Petrus Antonius De Man, Oss (NL); Rogier Christian Buijsman, Oss (NL); Jan Gerard Sterrenburg, Oss (NL); Joost Cornelis Marinus Uitdehaag, Oss (NL); Joeri Johannes Petrus De Wit, Oss (NL); and Guido Jenny Rudolf Zaman, Oss (NL)
Assigned to NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V., Oss (NL)
Appl. No. 17/579,990
Filed by NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V., Oss (NL)
PCT Filed Mar. 30, 2015, PCT No. PCT/EP2015/056839 § 371(c)(1), (2) Date Sep. 23, 2016, PCT Pub. No. WO2015/155042, PCT Pub. Date Oct. 15, 2015.
Application 17/579,990 is a continuation of application No. 16/728,900, filed on Dec. 27, 2019, granted, now RE48974, issued on Mar. 15, 2022.
Application 16/728,900 is a reissue of application No. 15/128,874, filed on Mar. 30, 2015, granted, now 9,856,258, issued on Jan. 2, 2018.
Application 17/579,990 is a reissue of application No. 15/128,874, filed on Mar. 30, 2015, granted, now 9,856,258, issued on Jan. 2, 2018.
Claims priority of application No. 14163734 (EP), filed on Apr. 7, 2014; and application No. 15153207 (EP), filed on Jan. 30, 2015.
13. A method of treating breast cancer, comprising administering an effective amount of the compound according to claim 1 [ N-(2,6-dimethylphenyl)-2-(2-methoxy-4-piperazin-1-yl-anilino)-5,6-dihydropyrimido[4,5-e]indolizine-7-carboxamide ] or a pharmaceutically acceptable salt thereof to a subject having breast cancer.